Betamethasone Dipropionate Spray Medical Necessity Criteria
Defines medical necessity, initial and continued therapy criteria, dosing limits, excluded indications, therapeutic alternatives, and approval durations for betamethasone dipropionate 0.05% spray (Sernivo) across Commercial, HIM, and Medicaid lines of business.
Product availability section updated strength per prescriber information.
HIM line of business added and references updated in 2020.
Template changes to other diagnoses/indications and continued therapy sections applied in 2022.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.